Semler settles DOJ FCA claims for $29.75M; warns Q4 revenue down at least 50% from Q3

Semler Scientific, Inc.

Settlement of $29.75M plus 4.25% annual interest from Apr 28, 2025 due in 14 business days; $5.2M+17.5% interest to relators, $390K fees to relators' counsel.
Semler admitted no wrongdoing; entered 5-year Corporate Integrity Agreement with HHS OIG requiring compliance measures.
Q3 2025 revenue expected $6.9-7.5M; a customer accounting for 44.9% of Q2 revenue significantly reducing QuantaFlo use from Oct 1.
Q4 2025 revenue expected at least 50% lower than Q3; new 510(k) clearance for expanded labeling not expected until mid-to-late 2026.
Securities class action filed Aug 29, 2025 alleging inadequate disclosure of DOJ investigation; Semler denies liability and will defend.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.